Alpha 1-antitrypsin deficiency medical therapy
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency medical therapy On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency medical therapy |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
|
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]Cafer Zorkun, M.D., Ph.D. [3]
Overview
Alpha 1-antitrypsin deficiency (A1AD) may be treated through intravenous infusions derived from donated human plasma.
Medical Therapy
In the United States, Canada, and several European countries, lung-affected A1AD patients may receive intravenous infusions of alpha-1 antitrypsin, derived from donated human plasma. This augmentation therapy is thought to arrest the course of the disease and halt any further damage to the lungs. Long-term studies of the effectiveness of A1AT replacement therapy are not available. It is currently recommended that patients begin augmentation therapy only after the onset of emphysema symptoms.
Augmentation therapy is not appropriate for liver-affected patients; treatment of A1AD-related liver damage focuses on alleviating the symptoms of the disease. In severe cases, liver transplantation may be necessary.
As α1-antitrypsin is an acute phase reactant, its transcription is markedly increased during inflammation elsewhere in response to increased interleukin-1 and 6 and TNFα production. Any treatment that blunts this response, specifically paracetamol (acetaminophen), can delay the accumulation of A1AT polymers in the liver and (hence) cirrhosis. A1AD patients are therefore encouraged to use paracetamol when slightly to moderately ill, even if they would otherwise not have used antipyretics.
- Treatment guidelines for AATD include:
- Alpha 1 antitrypsin enzyme repletion
- Smoking cessation
- Long-acting inhaled bronchodilators
- Preventive vaccinations against influenza and pneumococcus
- Pulmonary rehabilitation for patients with functional impairment
- Supplemental oxygen if needed
- Lung transplantation
- Treatment of COPD exacerbation in all patients of AATD should include AAT repletion.
- Augmentation therapy is the specific therapy for Alpha 1-antitrypsin deficiency (A1AD) associated lung disease.
- Augmentation therapy includes intravenous infusion of purified pooled human plasma alpha 1-antitrypsin deficiency to raise and maintain serum Alpha 1-antitrypsin levels above the threshold and to slow emphysema progression and enhance the duration and quality of life.
- Food and Drug Administration has approved four preparations of purified AAT.
- Following infusion AAT levels remain above the protective threshold for most of the dosing interval.
- The infused AAT has the ability to neutralize neutrophil elastase activity.
- Augmentation therapy recipients demonstrate a slower rate of FEV1 decline than nonrecipients
- Wencker and colleagues conducted a before-after study and found that the greatest effect of augmentation therapy in changing FEV1 slope was observed in individuals with a rapid FEV1 decline before augmentation therapy was initiated (ie, FEV1 decline 256 mL/y before therapy vs 53 mL/y during therapy).
- Bronchodilators are used for symptomatic relief of airflow obstruction and symptoms resulting from AATD and associated emphysema.
- Antibiotics can be used to treat bacterial complications, such as pneumonia or purulent bronchitis.
- Bronchodilators and antibiotics do not have any effect on disease progression.
- Corticosteroids can be used for short-term relief but have no proven long-term benefit in inhaled or oral preparations.
- Avoid oral steroids because of their long-term adverse effects.
- Oxygen is prescribed if patients are hypoxemic at rest or with activity.
- Replacement/Augmentation therapy is indicated to slow the progression of emphysema.
- Currently, IV augmentation therapy is the only FDA-approved treatment specific for AATD. It is indicated for patients with moderate degrees of airflow obstruction (FEV1 35-65% of predicted).
- Recommended dosage and route of administration is, 60 mg/kg/wk given IV.
- Respiratory enzymes are drugs used for long-term replacement in patients with clinical emphysema.
- Alpha1-proteinase inhibitor like Prolastin-C, Aralast NP, Glassia, Zemara is available for use in the United States.
- Respiratory enzymes are prepared from pooled human plasma by using a cold alcohol fractionation process followed by further purification steps to obtain a sterile, stable, lyophilized preparation of purified human alpha1-antiprotease inhibitor.
- Plasma is tested for HIV, hepatitis B, and hepatitis C before adding it to the product.
- In order to reduce the potential risk of infectious-agent transmission, solvent detergent mixer is added to the product, which serves to inactivate the viral agents